Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma.
Radiotherapy achieved local tumour control in most choroidal melanoma cases.
Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma.
Radiotherapy modalities such as iodine-125 (I 125 ) and ruthenium-106 (Ru 106 ) brachytherapy and proton beam radiotherapy (proton beam radiotherapy) are well established for the treatment of choroidal melanoma.
This study aimed to evaluate the rates of local tumour control, globe retention and visual acuity (visual acuity) outcomes in patients with choroidal melanoma treated with I 125 or Ru 106 brachytherapy or proton beam radiotherapy.
A review was conducted of all cases of choroidal melanoma treated with Ru 106 or I 125 brachytherapy or proton beam radiotherapy over a 10-year period.
The recurrence rates were 4.0%, 4.2% and 4.8% for Ru 106 , I 125 and proton beam radiotherapy, respectively.
Retention rates were 96.0% for Ru 106 , 94.4% for I 125 and 95.2% for proton beam radiotherapy.
LogMAR visual acuity of 1.0 or better was maintained in 50.9% of Ru 106 patients, 27.8% of I 125 patients and 39.7% of those treated with proton beam radiotherapy.
Each radiotherapy modality demonstrated high rates of local tumour control and globe retention.
The predictive nomogram may serve as a practical tool to support individualised visual prognostication and patient counselling in the management of choroidal melanoma.